Characterization of PAR1 and FGFR1 expression in invasive breast carcinomas: Prognostic significance

Oncology Letters

Volumn 4, Issue 4, 2012, Pages 647-657

  Tiburcio, Marta ^a,b   Costa, Sandra M A ^a   Duarte, Maria de Fatima ^c,d   Schmitt, Fernando C ^e,f   Filho, Adhemar Longatto ^a,g  

^a UNIVERSITY OF MINHO   (Portugal)

^b UNIVERSITY OF MINHO   (Portugal)

^c INSTITUTO POLITÉCNICO DE BEJA   (Portugal)

^d UNIVERSITY OF AVEIRO   (Portugal)

^e University of Porto   (Portugal)

^f UNIVERSITY OF PORTO   (Portugal)

^g UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Fibroblast growth factor receptor 1; Invasive breast cancer; Protease activated receptor 1

Indexed keywords

FIBROBLAST GROWTH FACTOR RECEPTOR 1; FORMALDEHYDE; MOLECULAR MARKER; PARAFFIN; PROTEINASE ACTIVATED RECEPTOR 1;

AGGRESSIVENESS; ANGIOGENESIS; ARTICLE; BREAST CARCINOMA; CANCER PROGNOSIS; CONTROLLED STUDY; CORRELATION ANALYSIS; HUMAN; INVASIVE CARCINOMA; MICROVASCULATURE; PHENOTYPE; PREDICTION; PROTEIN EXPRESSION; STROMA; TUMOR CELL; TUMOR GROWTH;

EID: 84864690484     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2012.806     Document Type: Article

References (33)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C and Parkin DM: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127: 2893-2917, 2010.
2. Weigelt B and Reis-Filho JS: Histological and molecular types of breast cancer: is there a unifying taxonomy? Nat Rev Clin Oncol 6: 718-730, 2009.
3. Weigelt B, Horlings HM, Kreike B, et al: Refinement of breast cancer classification by molecular characterization of histological special types. J Pathol 216: 141-150, 2008.
4. Hanahan D and Weinberg RA: Hallmarks of cancer: the next generation. Cell 144: 646-674, 2011.
5. Pusztai L: Current status of prognostic profiling in breast cancer. Oncologist 13: 350-360, 2008.
6. Yin YJ, Salah Z, Maoz M, et al: Oncogenic transformation induces tumour angiogenesis: a role for PAR1 activation. FASEB J 17: 163-174, 2003.
7. Winter SF, Acevedo VD, Gangula RD, et al: Conditional activation of FGFR1 in the prostate epithelium induces angiogenesis with concomitant differential regulation of Ang-1 and Ang-2. Oncogene 26: 4897-4907, 2007.
8. Agarwal A, Covic L, Sevigny LM, et al: Targeting a metalloprotease-PAR1 signaling system with cell-penetrating pepducins inhibits angiogenesis, ascites, and progression of ovarian cancer. Mol Cancer Ther 7: 2746-2757, 2008.
9. Vu TK, Hung DT, Wheaton VI and Coughlin SR: Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation. Cell 64: 1057-1068, 1991.
10. O'Brien PJ, Prevost N, Molino M, Hollinger MK, Woolkalis MJ, Woulfe DS and Brass LF: Thrombin responses in human endothelial cells. Contributions from receptors other than PAR1 include the transactivation of PAR2 by thrombin-cleaved PAR1. J Biol Chem 275: 13502-13509, 2000.
11. Boire A, Covic L, Agarwal A, et al: PAR1 is a matrix metalloprotease-1 receptor that promotes invasion and tumourigenesis of breast cancer cells. Cell 120: 303-313, 2005.
12. Bassus S, Herkert O, Kronemann N, et al: Thrombin causes vascular endothelial growth factor expression in vascular smooth muscle cells: role of reactive oxygen species. Arterioscler Thromb Vasc Biol 21: 1550-1555, 2001.
13. Duarte M, Kolev V, Soldi R, et al: Thrombin induces rapid PAR1-mediated non-classical FGF1 release. Biochem Biophys Res Commun 350: 604-609, 2006.
14. Delafontaine P, Anwar A, Lou H and Ku L: G-protein coupled and tyrosine kinase receptors: evidence that activation of the insulin-like growth factor I receptor is required for thrombin induced mitogenesis of rat aortic smooth muscle cells. J Clin Invest 97: 139-145, 1996.
15. Rauch BH, Millette E, Kenagy RD, et al: Thrombin- and factor Xa-induced DNA synthesis is mediated by transactivation of fibroblast growth factor receptor-1 in human vascular smooth muscle cells. Circ Res 94: 340-345, 2004.
16. Hernandez NA, Correa E, Avila EP, et al: PAR1 is selectively over expressed in high grade breast cancer patients: a cohort study. J Transl Med 7: 47, 2009.
17. D'Andrea MR, Derian CK, Santulli RJ and Andrade-Gordon P: Differential expression of protease activated receptors-1 and -2 in stromal fibroblasts of normal, benign, and malignant human tissues. Am J Pathol 158: 2031-2041, 2001.
18. Schwertfeger KL: Fibroblast growth factors in development and cancer: insights from the mammary and prostate glands. Curr Drug Targets 10: 632-644, 2009.
19. Welm BE, Freeman KW, Chen M, et al: Inducible dimerization of FGFR1: development of a mouse model to analyze progressive transformation of the mammary gland. J Cell Biol 157: 703-714, 2002.
20. Marinho A, Soares R, Ferro J, et al: Angiogenesis in breast cancer is related to age but not to other prognostic parameters. Pathol Res Pract 193: 267-273, 1997.
21. Brenton JD, Carey LA, Ahmed AA and Caldas C: Molecular classification and molecular forecasting of breast cancer: ready for clinical application? J Clin Oncol 23: 7350-7360, 2005.
22. Paredes J, Correia AL, Ribeiro AS, et al: Breast carcinomas that co-express E- and P-cadherin are associated with p120-catenin cytoplasmic localisation and poor patient survival. J Clin Pathol 61: 856-862, 2008.
23. Paredes J, Milanezi F, Viegas L, et al: P-cadherin expression is associated with high-grade ductal carcinoma in situ of the breast. Virchows Arch 440: 16-21, 2002.
24. Yang E, Boire A, Agarwal A, et al: Blockade of PAR1 signaling with cell-penetrating pepducins inhibits Akt survival pathways in breast cancer cells and suppresses tumour survival and metastasis. Cancer Res 69: 6223-6231, 2009.
25. Even-Ram S, Uziely B, Cohen P, et al: Thrombin receptor overexpression in malignant and physiological invasion processes. Nat Med 4: 909-914, 1998.
26. Bourdon JC: p53 and its isoforms in cancer. Br J Cancer 97: 277-282, 2007.
27. Suyama K, Shapiro I, Guttman M and Hazan RB: A signaling pathway leading to metastasis is controlled by N-cadherin and the FGF receptor. Cancer Cell 2: 301-314, 2002.
28. Xian W, Schwertfeger KL, Vargo-Gogola T and Rosen JM: Pleiotropic effects of FGFR1 on cell proliferation, survival, and migration in a 3D mammary epithelial cell model. J Cell Biol 171: 663-673, 2005.
29. Reis-Filho JS, Simpson PT, Turner NC, et al: FGFR1 emerges as a potential therapeutic target for lobular breast carcinomas. Clin Cancer Res 12: 6652-6662, 2006.
30. Elbauomy Elsheikh S, Green AR, Lambros MB, et al: FGFR1 amplification in breast carcinomas: a chromogenic in situ hybridisation analysis. Breast Cancer Res 9: R23, 2007.
31. Grose R and Dickson C: Fibroblast growth factor signaling in tumourigenesis. Cytokine Growth Factor Rev 16: 179-186, 2005.
32. Hasan J, Byers R and Jayson GC: Intratumoural microvessel density in human solid tumours. Br J Cancer 86: 1566-1577, 2002.
33. Lopes N, Sousa B, Vieira D, et al: Vessel density assessed by endoglin expression in breast carcinomas with different expression profiles. Histopathology 55: 594-599, 2009.